^
    6ms
    Beckman Coulter Life Sciences and Pillar Biosciences announce NGS application development pipeline for the Biomek NGeniuS System (Pillar Biosciences Press Release)
    "Beckman Coulter Life Sciences...announces a collaboration agreement with Pillar Biosciences, which develops and distributes IVD & RUO NGS testing solutions based on their proprietary SLIMamp® technology to help localize patient testing and optimize the selection of precision therapies for cancer patients...The application development partnership is initially focused on five commercially-available, solid tumor liquid biopsy and hematology panels from Pillar Biosciences..."
    Licensing / partnership
    |
    OncoReveal™ Solid Tumor Panel • oncoReveal™ Core LBx • oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel • oncoReveal™ Solid Tumor v2 Panel
    6ms
    To UMI or not to UMI: Obtaining robust low-frequency variant identification for liquid biopsy with a SLIMamp-based NGS chemistry without molecular barcoding (AMP 2023)
    Our findings indicate that using our SLIMamp chemistry, achieving high sensitivity and specificity in detecting low-frequency variants in cfDNA samples by nextgeneration sequencing testing does not necessitate the use of UMIs. Instead, implementing a robust post-sequencing computational strategy in non-UMI protocols using in- or out-of-batch normal control can yield equivalent or improved assay performance.
    Liquid biopsy • Next-generation sequencing • Biopsy
    |
    oncoReveal™ Core LBx
    6ms
    Robust detection of Copy Number Amplifications using Pillar's oncoReveal™ Core LBx panel with low input from liquid biopsy samples (AMP 2023)
    CNA calling is challenging for focused panels with low DNA input and low CNs. oncoCNA addresses this challenge by accurately and consistently calling CNs with as little as 10ng cfDNA and 1.2 copy number ratio, enabling rapid and cost-effective on-site LBx NGS testing at any pathology lab.
    Liquid biopsy • Biopsy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    oncoReveal™ Core LBx
    6ms
    Robust low frequency somatic variant detection in cfDNA using a SLIMamp® based liquid biopsy assay (AMP 2023)
    We demonstrate here a low-cost, kitted, amplicon-based LBx panel that can detect clinically significant, high-priority variants down to 0.1% VAF, without the use of UMIs that can be run at scale on a mid-throughput Illumina NextSeq 550 NGS platform, enabling greater opportunity for labs to perform LBx testing within their own laboratories. The panel was able to amplify and detect variants even in samples with limited DNA input <10ng. The panel's performance was not affected by the choice of extraction strategy used.
    Liquid biopsy • Biopsy • Cell-free DNA
    |
    oncoReveal™ Core LBx
    6ms
    Detection of Microsatellite Instability (MSI) Using oncoReveal Core LBx, a Multiplexed, Single Tube, Liquid Biopsy Assay (AMP 2023)
    We developed a cfDNA assay for MSI detection in addition to SNV/indel and CNV detection. We demonstrate high performance with matched and unmatched normals, supporting the feasibility of such panels for liquid biopsy testing.
    Liquid biopsy • Microsatellite instability • MSi-H Biomarker • IO biomarker • Biopsy
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    oncoReveal™ Core LBx
    8ms
    Pillar Biosciences launches oncoReveal™ Core LBx, an NGS kit to enable localized liquid biopsy testing (PRNewswire)
    "Pillar Biosciences, Inc...has announced the global launch of oncoReveal™ Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a solution for liquid biopsy-based pan-cancer tumor profiling. The oncoReveal Core LBx is the latest addition to Pillar Biosciences' portfolio of cancer profiling assays designed to enable localized testing and reduce time to treatment initiation."
    Launch
    |
    oncoReveal™ Core LBx